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Abstract 
Diabetes and diabetic complications are considered as leading causes of both morbidity and mortality in the world. 
Unfortunately, routine medical treatments used for affected patients possess undesirable side effects, including 
kidney and liver damages as well as gastrointestinal adverse reactions. Therefore, exploring the novel therapeutic 
strategies for diabetic patients is a crucial issue. It has been recently shown that melatonin, as main product of the 
pineal gland, despite its various pharmacological features including anticancer, anti-aging, antioxidant and anti-
inflammatory effects, exerts anti-diabetic properties through regulating various cellular mechanisms. The aim of the 
present review is to describe potential roles of melatonin in the treatment of diabetes and its complications.
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Background
Diabetes mellitus (DM), a frequent life-threatening met-
abolic disorder worldwide, is characterized by hyper-
glycemia caused by either insulin resistance or declined 
insulin secretion [1]. In the last decades, the incidence of 
diabetes mellitus has been enhancing [2, 3]. This disease 
has been one of the leading cause of death worldwide, 
and the International Diabetes Mellitus Federation esti-
mated that 592 million people will suffer from diabetes 
mellitus by the year 2035 [4]. Several investigations have 
indicated that diabetes mellitus, could mediate various 
complications, including diabetic cardiovascular compli-
cations, diabetic neuropathy, retinopathy, nephropathy 
and liver complications, which have been the main causes 
of its mortality and morbidity [4, 5]. Thus, it is essential 
to search for efficient methods for the management and 
prevention of diabetes mellitus and its complications [6].
The impact of pineal hormone on insulin secretion, 
carbohydrate metabolism and blood glucose has been 
recently demonstrated. Melatonin (N-acetyl-5-meth-
oxytryptamine), a tryptophan-derived endocrine agent, 
is mainly synthetized by the pineal gland and locally by 
numerous other tissues [7]. Despite the higher insulin 
levels in diabetic subjects, diabetes mellitus is accom-
panied by lower serum concentrations of melatonin in 
diabetic GotoKakizaki rats [8]. Furthermore, melatonin 
functions as an anti-aging [9], anti-inflammatory, anti-
oxidant [10] as well as antihypertensive agent [11]. This 
review summarizes the therapeutic potentials of mela-
tonin in the treatment of diabetes mellitus and its com-
plications, based on findings of recent studies.
Melatonin: potentials, safety and bioavailability
Melatonin, a broad spectrum antioxidant, can be used 
in various pathologic conditions mainly due to its regu-
latory effects on autophagy, endoplasmic reticulum (ER) 
stress, and oxidative stress. This molecule has poten-
tial therapeutic effects for treating neurodegenerative 
diseases, malignancies, cardiovascular diseases and 
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regulatory role in sleep disorders and reproduction [13, 
14]. Furthermore, melatonin has immunomodulatory 
effect [15], which depends on its capability to increase 
the cytokines production and its anti-apoptotic and anti-
oxidant properties. By affecting cytokine release from 
immunocompetent cells, melatonin has been suggested 
to modulate the immune system [16]. Melatonin modu-
lates reproduction by regulating the production of sex 
hormones in seasonally breeding animals. In long-breed-
ers, melatonin decreases estrogen production. However 
in short-breeders, melatonin increases the level of estro-
gen synthesis in winter [17, 18]. In humans, melatonin 
role on reproduction is not totally clear. During the dark 
season, the high level of melatonin is associated with the 
low estrogen production rate [19]. In addition, melatonin 
directly increases the steroidogenesis in human granu-
losa-luteal cells [20]. Furthermore, melatonin increases 
progesterone production via its M2 receptors on corpus 
luteum [21]. However, there are reports that indicate no 
role for melatonin in up-regulating estrogen synthesis 
by granulosa cells [22]. Taken together, melatonin affects 
the activity of ovaries; however this control and the exact 
mechanisms remain to be determined.
As mentioned earlier, melatonin is a very potent anti-
oxidant partially due to its molecule structure which is 
both lipophilic and hydrophilic, so it can cross all bio-
barriers easily and accumulate in high amounts within 
subcellular organelles including mitochondria which are 
the main sites for reactive oxygen species (ROS) produc-
tion [23–26]. The anti-oxidative effects of melatonin is 
attributed to its direct free radical scavenging properties 
as well as inducing the production of other anti-oxidant 
enzymes including glutathione peroxidase (GPx), glu-
tathione reductase (GR), catalase (CAT) and superox-
ide dismutase (SOD) [27–30]. Melatonin also inhibits 
the expression of pro-oxidant enzymes such as nitric 
oxide (NO) synthase (NOS), cyclooxygenase-2 (COX-
2), myeloperoxidase and eosinophil peroxidase [31, 32]. 
Free radicals such as ROS are waste products of cellular 
metabolism. The accumulation of these agents within 
cells can cause damage to cell DNA, proteins and lipids 
and may give rise to cancerous cells. Melatonin can avoid 
these damages by neutralizing free radicals [30, 33, 34].
The safety of exogenous melatonin is still under inves-
tigation; however, with the limiting data available, 
melatonin can be considered as a safe drug. Melatonin 
administration for adolescents, children and preterm 
infants with different diseases has shown no significant 
side effects except at high doses or multiple time admin-
istration [35–37]. Of note, melatonin could affect sexual 
maturation in the mentioned groups [38]. In adults, oral 
administration of melatonin for improving of dyspnea 
(3  mg fast release for 3  months) in chronic obstructive 
pulmonary disease (COPD) patients and protecting the 
patients from depression and anxiety after breast can-
cer surgery (6 mg for 3 months) has shown no major side 
effects. However, minor adverse effects such as transient 
dizziness, headache, numbness, paresthesia of mouth, 
arms or legs, and deterioration of dyspnea has been con-
siderable in oral administration [39, 40]. Melatonin use 
(9 mg sustained release per day for 4 weeks) in order to 
improve the sleep quality of the children with epilepsy 
had some adverse effects including: morning drowsiness, 
gastrointestinal symptoms, increased enuresis, headache, 
dizziness, diarrhea, rash, and hypothermia [41].
Since melatonin is mainly metabolized by cytochrome 
P450 (CYP) 1A2 and CYP2C19, inhibitors of these 
enzymes lead to higher concentration of melatonin in 
the body [42]. Melatonin lowers blood pressure and glu-
cose level, therefore, patients receiving antihypertensive 
or blood glucose lowering drugs should use melatonin 
with cautious [43]. Since the administration of melatonin 
during pregnancy is not studied, its use is not recom-
mended for pregnant women [38]. The use of melatonin 
by breastfeeding women causes daytime drowsiness for 
their infants [44].
Pharmacokinetics and optimal dosage of this therapeu-
tic agent are not thoroughly clear yet and more studies 
are required on these subjects; however, there are some 
inconsistent studies on oral and intravenous adminis-
tration of melatonin. The absorption of this hormone 
is site dependent making the rectum as the site with 
the highest absorption rate. Orally administered mela-
tonin at doses up to 80 mg is absorbed fast and follows 
first-order kinetic [45]. Melatonin is expected to reach 
maximal plasma concentration after 30–45  min and 
30–60 min (t max) in intravenous (IV) and oral admin-
istration, respectively [46, 47]. The elimination rate of 
melatonin from the body depends on the dose and route 
of administration. Because of structural characteristics, 
melatonin is both water and lipid soluble. So, it can run 
through tissues, cells and cellular compartments easily 
[48]. The elimination half-life (t1/2) for 100 mg melatonin 
in IV administration is 45 min [46], while it is 28–61 min 
for 0.005–2  mg [49]. The elimination half-life for oral 
administration of melatonin is a little higher and is about 
46–65 min for 0.5–6 mg [47]. Melatonin is considered a 
drug with a high hepatic first pass effect. In oral admin-
istration, just 10–15% of melatonin reaches the systemic 
circulation and the rest of it is metabolized by CYP1A2 
to 6-hydroxymelatonin and excreted in the urine after 
conjugation with sulfate or glucuronic acid [48, 50–53]. 
Of note, melatonin elimination occurs faster in chil-
dren in comparison to adults [54]. Low absorption from 
the gastrointestinal tract, high first-pass effect and high 
rate of metabolizing make melatonin a drug with low 
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bioavailability [53]. Because of poor bioavailability, other 
routes of administration are suggested; for example: sub-
cutaneous injection, transdermal, oral transmucosal and 
intranasal [43, 55].
Anti‑diabetic effects of Melatonin
Melatonin has been shown to have a beneficial role in 
controlling blood glucose in both animal and human 
studies. The expression level of glucose transporter type 
4 (GLUT4) gene is reduced in pinealectomized ani-
mals, which consequently results in glucose intolerance 
and insulin resistance. These conditions are alleviated 
by melatonin treatment [56, 57].  Furthermore, the level 
of melatonin decreases in  human dental pulp tissue  in 
type 2 diabetic participants. Melatonin in pharmacologi-
cal  concentration could improve  iNOS and SOD activ-
ity in hyperglyceamic human dental pulp cells (hDPCs), 
suggesting the protective effects of melatonin in human 
dental pulp tissue under hyperglycaemia [58].   In rats 
with streptozotocin (STZ)-induced diabetes, eight-week 
treatment with insulin (NPH, 1.5 U/100gr/day) and mela-
tonin (0.2 mg/kg/day in drinking water) improves glucose 
homeostasis and insulin sensitivity of white adipose tis-
sue comparing with using one of these drugs individu-
ally [59]. The production of melatonin has been reported 
to reduce in animal models of diabetes and melatonin 
treatment (100 mg/kg/day in drinking water for 8 weeks) 
in high-fat diet-fed mouse with insulin resistance results 
in better glucose tolerance [60]. Diabetes also results in 
decreased testosterone production. It has been shown 
that melatonin (10 mcg/kg/day in drinking water) is able 
ameliorate the deleterious effects of diabetes on testos-
terone production in rats by improving glucose metabo-
lism in the Leydig cells and inducing acetate production 
which is a precursor for cholesterol synthesis [61].
Patients with type 2 diabetes mellitus (T2DM) have a 
lower nocturnal melatonin production compared to ones 
without diabetes [62]. Several studies indicated that sin-
gle dose of melatonin in healthy post-menopausal and 
pre-menopausal women (1  mg and 5  mg respectively) 
worsens the glucose tolerance test in the morning and the 
evening [63, 64]. On the other hand, chronic treatment 
with prolonged-release melatonin (2 mg) over a 5-month 
period decreases the level of HbA1c and betters glycemic 
control [65]. Furthermore, administration of melatonin 
(6 mg) for 3 months resulted in better glycemic control 
in patients with T2DM [66]. In patients with poorly con-
trolled T2DM, addition of melatonin (10  mg) and zinc 
acetate (50 mg) to metformin resulted in the better tissue 
response to metformin alone [67]. In obese patients with 
Acanthosis Nigricans, melatonin (3 mg/day) supplemen-
tation for 12 weeks improved insulin sensitivity as well as 
inflammatory status [57].
Oxidative stress, which has an important role in the 
induction of various complications of diseases such as 
diabetes, is effectively attenuated by the anti-oxidative 
activity of melatonin. Moreover, this hormone protects 
the beta cells of pancreas, with low antioxidant content, 
by neutralizing reactive oxygen species [68, 69]. Based on 
a recent systematic review, melatonin may have a poten-
tial role in better glycemic control through increasing 
insulin sensitivity and lowering fasting glucose [70].
Melatonin and diabetic complications
As mentioned above, diabetes mellitus causes numer-
ous micro- and macrovascular complications in affected 
patients. Melatonin is considered as an appropriate can-
didate for the prevention and treatment of diabetes melli-
tus complications. Here, we discuss about its therapeutic 
potentials for cardiomyopathy, retinopathy, central nerv-
ous system (CNS)-related complications of diabetes, neu-
ropathy, and nephropathy.
Effects of melatonin on diabetic cardiomyopathy
Diabetic cardiomyopathy is a common complication of 
diabetes mellitus, which is defined as adverse changes 
in myocardial structure and function in the absence of 
other cardiac risk factors including coronary artery dis-
ease or hypertension [71]. Diabetic cardiomyopathy is 
characterized by increased myocardial fibrosis and stiff-
ness, with this being associated with the impaired  dias-
tolic function, late systolic dysfunction resulting in the 
inability of the heart to pump enough blood through the 
body, a state called heart failure [72]. The main pathoge-
netic factors involved in the development and progres-
sion of diabetic cardiomyopathy include hyperglycemia, 
systemic insulin resistance, and impaired cardiac insulin 
metabolic signaling; these factors induce several path-
ways including vascular endothelial dysfunction, adr-
energic activity, impairment of mitochondria calcium 
 (Ca2+) handling, activation of renin–angiotensin system, 
myocardial ischemia/functional hypoxia, oxidative stress, 
mitochondria dysfunction, inflammation, endoplasmic 
reticulum stress and cardiomyocyte death [72, 73]. Exces-
sive level of reactive oxygen species (ROS) induced by 
high glucose contributes to the peroxidation of lipids, 
induction of apoptosis and inhibition of autophagy in 
muscle fibers [74]; diabetes impairs myocardial mito-
chondrial biogenesis and suppresses the activity of myo-
cardial mitochondrial Complexes I, III and IV resulting in 
the loss of mitochondrial number, impairment of mito-
chondrial function, increased generation of ROS and 
escape of death‐inducing factors [75]. Although hyper-
glycemia increases the risk of cardiomyopathy in diabetic 
patients and good glycemic control lowers the progres-
sion of diabetic microvascular complications, intensive 
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glucose control in patients with established diabetes 
mellitus cannot reduce the mortality  induced by dia-
betic cardiomyopathy [76]. This highlights the need for 
effective therapeutic agents to prevent or treat diabetic 
cardiomyopathy.
Melatonin as an effective antioxidant has been demon-
strated to prevent diabetes-induced harmful effects on 
the heart (Fig. 1a). Melatonin reduces oxidative damage 
in myocardial cells and inhibits extrinsic and intrinsic 
pathways of apoptosis; in STZ‐induced diabetic rats, mel-
atonin improves antioxidative status and reduces lipid 
peroxidation level and apoptotic markers in heart tissue 
to near control values [77, 78]. Melatonin preserves mito-
chondrial function in cardiac of diabetic rats through 
increasing the mitochondrial biogenesis and deacetyla-
tion of mitochondrial anti-oxidative enzymes, which this 
effect results from activation of cGMP-PKGIα, sirtuin-1 
(SIRT1)‐peroxisome proliferator-activated receptor 
gamma coactivator 1α (PGC1α) and 5′ AMP-activated 
protein kinase (AMPK)-PGC1α-SIRT3 signaling path-
ways [79–81]. Activation of PGC1α-SIRT3 signaling 
plays a key role in cardioprotective action of melatonin; 
this signaling pathway leads to the enhancement of 
mitochondrial SOD activity, oxidative phosphorylation 
of Complexes I, III and IV, and reduction of mitochon-
drial lipid peroxidation, ROS generation and myocardial 
apoptosis [79]. In addition, it has been emphasized that 
melatonin treatment ameliorates myocardial apopto-
sis through suppressing ER-stress and spleen  tyrosine 
kinase  (Syk)/mitochondrial complex I/sarcoendoplasmic 
reticulum calcium transport ATPase (SERCA)  axis [82, 
83]. Chronic high-glucose activates Syk leading to the 
repression of the expression and activity of mitochondrial 
complex I causing increased generation of ROS and sub-
sequent peroxidation of SERCA; this results in the inhi-
bition of cytoplasmic calcium  re-uptake  by ER leading 
to cellular calcium overload and cardiomyocytes death 
via activation of mitochondria‐ and ER stress‐mediated 
apoptosis [82, 83].
Melatonin modulates nuclear factor erythroid 
2-related factor 2  (NRF2)-hemeoxygenase 1 (HO-1) 
and mitogen-activated protein kinase (MAPK) sign-
aling through activating membrane receptors (espe-
cially MT2  receptor)-dependent cyclic guanosine 
monophosphate (cGMP)-protein kinase G Iα (PKGIα) 
signaling pathway, which contributes to the improve-
ment of diabetic cardiac function by inhibiting myo-
cardial apoptosis and  oxidative stress [80]. Activation 
of SIRT1‐PGC1α  pathway by melatonin contributes 
to the inhibition of dynamin‐related protein 1 (Drp1)‐
mediated mitochondrial fission, suppression of oxida-
tive stress, reduction of cardiomyocyte apoptosis, and 
improvement of mitochondrial and cardiac function in 
STZ‐induced diabetic mice [81]. Furthermore, maternal 
melatonin treatment improves the tolerance to myocar-
dial ischemia/reperfusion injury in diabetic mother–off-
spring mice. This beneficial effect of melatonin results 
from activation of cardiac insulin receptor substrate 
(IRS)‐1/Protein kinase B (Akt) signaling leading to the 
suppression of mitochondria‐ and ER stress-mediated 
apoptosis and oxidative stress [84]. Co-administration 
of PPAR-g agonist, thiazolidinediones, with melatonin 
has been reported to have beneficial effects on diabetes-
induced cardiovascular complications. Combination of 
pioglitazone or rosiglitazone with melatonin is effective 
to normalize levels of SOD, glutathione (GSH), CAT, and 
lipid peroxidation as well as inhibit myonecrosis, vacu-
olar changes and infiltration of inflammatory cells in the 
heart tissue of alloxan-induced diabetic rats; this indi-
cates that melatonin may be a potential drug to increase 
beneficial effect of thiazolidinediones on diabetic cardio-
myopathy [73]. Melatonin treatment may also prevent 
the development of diabetic cardiomyopathy through 
increasing the phosphorylation of vascular endothelial 
growth factor-A (VEGF-A) resulting in the inhibition of 
cardiac enlargement and hypertrophy in STZ-induced 
diabetic rats [85].
The protective effect of melatonin against diabetic 
cardiomyopathy may also result from its modula-
tory effect on autophagy pathway. Melatonin has been 
reported to alleviate cardiac remodeling through inhib-
iting the expression of mammalian target of rapamycin 
(mTOR);  mTOR is an  important molecule inhibiting 
autophagy pathway, which remarkably elevates in the 
myocardium of diabetic rats leading to the occurrence 
of  both cardiomyopathy and cardiac hypertrophy [74]. 
Melatonin also regulates the activity of mammalian 
Ste20-like kinase 1 (Mst1)/Sirt3 signaling pathway. Sup-
pression of Mst1 by melatonin contributes to the up-
regulation of autophagy/Parkin-mediated mitophagy, 
inhibition of apoptosis and modulation of mitochondrial 
integrity and biogenesis leading to the alleviation of car-
diac remodeling and dysfunction in diabetic mice [86, 
87]. Table 1 summarizes studies indicating the protective 
effects of melatonin on diabetic cardiomyopathy.
The therapeutic effects of melatonin on diabetic 
retinopathy
Diabetic retinopathy (DR), a prevalent asymptomatic 
microvascular complication of diabetes mellitus, is a 
leading cause of vision loss worldwide [88, 89]. Accord-
ing to recent reports, one-third of diabetic patients pos-
sess some degree of diabetic retinopathy [90]. Due to the 
increasing prevalence of diabetes worldwide, the number 
of diabetic retinopathy patients has been estimated to 
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Fig. 1 a Melatonin improves diabetic cardiomyopathy through inhibiting mitochondrial fission by activation of SIRT1‐PGC1α pathway, increasing 
mitochondrial biogenesis by activation of cGMP-PKGIα, SIRT1 and AMPK-PGC1α-SIRT3 signaling pathways, inhibiting cardiac hypertrophy by 
reduction of the expression of VEGF-A, inhibiting apoptotic pathway by decrease the expression of caspase-3, -9, -8, Bax, PERK, Syk/MC1/SERCA, 
IRS-1/Akt and MAPK signaling pathways and inhibiting oxidative stress by increase the activity of SOD, CAT, GPx, cGMP-PKGIα and Nrf-2-HO-1 
signaling pathways and the level of GSH and reduction of ROS, MDA and NO levels. b Melatonin reduces diabetic retinopathy through inhibiting 
oxidative stress by reduction of ROS, MDA and NO levels and activation of CAT and PI3K/Akt-Nrf2 pathway, improving blood-retinal barrier by 
reduction of the expression of HIF-1α, VEGF-A and PEDF, inhibiting apoptotic pathway by decrease the expression of caspase-3, Bax and MAPKs 
pathways, and inhibiting inflammation by inhibition of the expression of TNF-α, NOS and the activity of NFκB. c Melatonin ameliorates diabetic 
neuropathy through inhibiting oxidative stress by increasing CAT, SOD and GPx activity and GSH level and activating Nrf-2-HO-1 pathway, inhibiting 
inflammation by reduction of TNF-α, iNOS, IL-6 and COX-2 expressions and the activity of NFκB, inhibiting apoptotic pathway by alleviation of 
the expression of caspase-3 and -9, Bax, PARP, and p38 MAPKs and elevation of PINK-1 level, and increasing the level of GABA and decreasing 
astrogliosis, which this effect leads to the improvement of memory and cognitive ability. d Melatonin improves diabetic nephropathy through 
inhibiting fibrotic process by reduction of the expression of TGF-β, inhibiting oxidative stress by enhancement of mitochondrial complex III, 
CAT, SOD, GPx and GST activities and reduction of NOX activity and MDA and NO generation, inhibiting inflammation by decreasing the level 
of IL-β, IL-6 and IL-33, inhibiting apoptosis by reduction of caspase-3 and Bax expression and JAK/STAT activity, inducing autophagy pathway by 
enhancement of the expression of Beclin-1, and inhibiting EMT by elevation the level of miR-49, which results in the alleviation of the level of ROCK. 
SIRT sirtuin, PGC1α peroxisome proliferator-activated receptor gamma coactivator 1α, AMPK 5′ AMP-activated protein kinase, cGMP Cyclic guanosine 
monophosphate, PKGIα Protein kinase G Iα, VEGF-A Vascular endothelial growth factor-A, Syk Spleen tyrosine kinase, SERCA sarcoendoplasmic 
reticulum calcium transport ATPase, Nrf2 erythroid 2‐related factor 2, HO-1 heme oxygenase-1, IRS‐1 insulin receptor substrate, Akt Protein kinase 
B, GPx glutathione peroxidase, CAT catalase, SOD superoxide dismutase, NOS NO synthase, iNOS inducible NOS, MDA malondialdehyde, COX-2 
cyclooxygenase-2, ROS reactive oxygen species, NF‐κB nuclear factor-κB, TNF-α tumor necrosis factor α, IL interleukin, mTOR mammalian target of 
rapamycin, GSH glutathione, NO nitric oxide, JAK janus kinase, STAT signal transducer and activator of transcription, GABA gamma-aminobutyric acid, 
PARP poly(ADP-ribose) polymerase, MAPK mitogen-activated protein kinase, TGF-β transforming growth factor-β, EMT endothelial-to-mesenchymal 
transition, ROCK RhoA/Rho kinase, GST glutathione S-transferases, NOX NADPH oxidase
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elevate from 424.9 million in 2017 to 628 million by 2045 
[91].
Nowadays, as mentioned earlier, inflammation and 
oxidative stress have crucial roles in diabetic retinopathy 
pathogenesis [92, 93]. Therefore, treatments such as mel-
atonin restricting inflammatory and oxidative impacts 
of diabetes mellitus could be greatly potential to affect 
individuals through preventing or decreasing the retinal 
complications (Fig. 1b).
Various and heterogeneous factors, such as advanced 
glycation end products (AGEs), growth factors, 
hyperglycaemia as well as great levels of vitreous or cir-
culating chemokines, cytokines and ROS can trigger the 
inflammatory responses in the retinal vasculature [94, 
95]. Thus, mounting evidence suggests chronic inflam-
mation as an essential process in the development of dia-
betic retinopathy, primarily in early stages [96].
Several investigations have shown enhanced levels of 
different pro-inflammatory cytokines, including COX2, 
inducible NO synthase (iNOS), nuclear factor kappa B 
(NF-κB), intercellular adhesion molecule-1 (ICAM), and 
vascular endothelial growth factor (VEGF) in the retinas 
Table 1 Investigations on melatonin and diabetic cardiomyopathy
Type of study Route of melatonin 
administration
Treatment duration Target Effect Refs.
In vivo dose (animal) In vitro 
concentration (cell 
type)
50 mg/kg/day (male 
Wistar rats)








50 mg/kg/day (male 
Wistar rats)
– Intraperitoneal 56 days VEGF-A Antioxidant effects























10 mg/kg/day (male 
Sprague–Dawley 
rats)














10 mg/kg/day (male 
Wistar rats)
– Oral 21 days Caspase-3, Caspase-8, 
Caspase-9
Antioxidant effects [78]
10 mg/kg/day (female 
Wistar strain rats)




10 mg/kg/day (male 
Sprague–Dawley 
rats)
10 μmol/l (H9c2) Oral (for 5 days before 
the surgery)
Intraperitoneal (once 
10 min before the 
reperfusion)







10 mg/kg/day (male 
Sprague–Dawley 
rats)
10 μM (H9c2) Oral (for 5 days before 
the surgery)
Intraperitoneal (once 
10 min before the 
reperfusion)
5 days cGMP-PKGIα, Nrf-









10 mg/kg/day (female 
C57BL/6 mice)
– Intraperitoneal Until the end of gesta-
tion
IRS-1/Akt signaling Ameliorative effects 
on myocardial 
ischemia–reperfu-
sion in diabetic 
pregnancy
[84]
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and vitreous humours of diabetic animals and humans 
[92, 97, 98]. Although various stimuli are able to promote 
the production of VEGF leading to pathological angio-
genesis during retinal hypoxia [99], oxidative stress has 
a key role via enhancing the level of growth factor and 
mediating the evolution of diabetic retinopathy to patho-
logical advanced stages. Utilizing retinal pigment epithe-
lial cells, Simão and colleagues showed that high levels 
of glucose regulate the expression of different VEGF iso-
forms through ROS generation [100].
Melatonin synthesis has been reported to reduce in 
diabetic rats, which this is characterized by the aryla-
lkylamine N‐acetyl transferase (AANAT) activity reduc-
tion, as a significant enzyme regulating melatonin daily 
production; insulin therapy has been reported to ame-
liorate decreased melatonin levels [101, 102]. In agree-
ment with these findings, Hikichi et al. also reported that 
nighttime  levels of melatonin were considerably lower 
in diabetic patients compared to non-diabetic subjects, 
and these levels were lower in patients with prolifera-
tive  diabetic retinopathy than non-proliferative  diabetic 
retinopathy individuals [103]. In diabetic rats, mela-
tonin reduces histopathological alterations of the retina 
through decreasing oxidative stress [104]. Dehdashtian 
et  al. [30] reviewed the involvement of inflammation, 
oxidative stress and autophagy in the pathogenesis of dia-
betic retinopathy. They indicated that melatonin is able 
to modulate autophagy cascade and diminishes oxida-
tive stress and inflammation. Melatonin enhances cel-
lular antioxidant defenses and reduces the production 
of VEGF in Müller cells through activating the PI3K/
Akt-Nrf2 signaling pathway; these anti-angiogenic and 
anti-oxidative effects of melatonin in Müller cells have 
shown to be receptor-dependent [105]. Melatonin treat-
ment triggers Akt-Nrf2-induced antioxidant system and 
suppresses NF-κB pathway; it is suggested that regulat-
ing retinal melatonin and its receptors could be a benefi-
cial method for treatment of diabetic retinopathy [106]. 
Melatonin reduces the mean scores of fluorescein leakage 
and the level of ROS and malondialdehyde (MDA) as well 
as suppresses the apoptosis and inflammation in rats with 
diabetic retinopathy through repressing the MAPK path-
way [107, 108].
Djordjevic et  al. [109] investigated the protective 
effects of melatonin on retina in pre-diabetic condi-
tions. They showed that oral administration of melatonin 
(85  μg/animal/day) increases HDL cholesterol con-
centrations in treated rats and decreases fructosamine 
and fasting serum glucose levels. In addition, it affected 
quantitative insulin sensitivity check index and serum 
insulin in treated groups but had no considerable effects 
on non-fasting glucose. Totally, melatonin supplementa-
tion significantly diminished matrix metallopeptidase 
9 (MMP9), VEGF, iNOS, advanced oxidation protein 
products (AOPP), and MDA levels, hence showing over-
all positive antioxidant impacts as well as pro-angiogenic 
signaling in the pre-diabetic retina. Ma and his colleagues 
investigated the therapeutic effects of melatonin on dia-
betic retinopathy rats. They showed that the expression 
of Bax, a pro-apoptotic gene, significantly increases in the 
retina of diabetic retinopathy rats, while the expression of 
Bcl-2, an anti-apoptosis gene, decreases. After melatonin 
therapy, the serum levels of interleukin (IL)-1β and IL-18 
also reduces. These results showed that melatonin has 
Table 2 Effects of melatonin on diabetic retinopathy reported by various investigations
Type of study Route 
of administration
Treatment duration Target Effect(s) Refs.
In vivo dose (animal) In vitro 
concentration (cell 
type)
10 mg/kg/day (male 
Sprague–Dawley 
rats)






10 mg/kg/day (male 
Wistar rats)
– Intraperitoneal 4 weeks HIF-1α, VEGF-A, PEDF Antioxidant effects [110]
20 mg (male Wistar 
rats)
– Subcutaneous pellet 12 weeks NOS, TNF-α, CAT, Protective effects on 
the retina against 
the alterations
[196]
20 mg/kg/day (male 
WISTAR rats)
– Oral 7 weeks MDA, ROS Protective effects on 
the retina against 
the alterations
[108]
10 mg/kg/day (male 
Sprague–Dawley 
rats)
– Intraperitoneal 12 weeks glutamate cysteine 






– 10 nM–0.1 mM (Mül-
ler cells)
– 48 h VEGF, Akt Antioxidant effects [105]
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anti-inflammatory and anti-apoptosis effects in rats with 
diabetic retinopathy [107]. Ozdemir et  al. [110] showed 
that daily intraperitoneal administration of melatonin for 
12 weeks declines retinal levels of MDA and nitrotyros-
ine, indicating an antioxidant support. Melatonin also 
normalizes retinal vascular alterations through decreas-
ing the vasculoregulator cytokines. Studies reporting 
melatonin effects on diabetic retinopathy have been illus-
trated in Table 2.
The therapeutic effects of melatonin on diabetic neuronal 
complications
Melatonin and CNS‑related complications of diabetes
Cognitive functions Acute and chronic vascular and 
metabolic perturbations impair the structural and func-
tional brain integrity in diabetic patients. In other words, 
DM contributes to various structural and functional dis-
orders related to peripheral and central nervous systems 
[111].
Cerebrovascular alterations, such as neurotropic 
changes like decreased IGF (insulin growth factor) lev-
els, disrupted vascular reactivity, and attenuated blood 
flow to the brain demonstrate that mentioned aberra-
tions precede apoptotic neuronal loss as well as func-
tional cognitive disturbances in hippocampus [112, 
113]. DM is correlated with moderate impairment in 
cognitive functions, Alzheimer’s disease and dementia 
[114–117]. Cognitive deficit is probably linked to hyper-
glycemia neurotoxic impacts and alterations in neuronal 
and neurotransmission functionalities. Enhanced oxida-
tive stress promotes oxidative damages in multiple brain 
regions, such as the hippocampus [118]. As mentioned 
above, oxidative stress plays key contributory roles in the 
development of diabetic complications, while antioxidant 
treatment may restore or protect physiological func-
tions [118]. Prior researchers have reported that antioxi-
dants decrease the hippocampal neuronal cell damages 
induced by diabetes-mediated excitotoxicity [119–121]. 
It has been revealed that free radical scavengers pro-
tect neurons from diverse neurodegenerative situations. 
Melatonin, by its antioxidant ability, has been indicated 
to exert neuroprotective effects under different circum-
stances [122, 123].
In a study, Tuzuc and colleagues examined and com-
pared the vitamin E and melatonin impacts on  cogni-
tive  function of diabetic animals. Memory and learning 
behaviors were studies utilizing a spatial version of the 
Morris water maze test. Glutathione and lipid peroxi-
dation levels were measured in frontal cortex and hip-
pocampus. The diabetic animals developed considerable 
impairments in memory and learning behaviors in com-
parison with control rats. Moreover, the concentra-
tion of glutathione is reduced and the level of lipid 
peroxidation is enhanced in diabetic animals. Vitamin E 
and melatonin remarkably improved memory and learn-
ing performance. In addition, glutathione levels and 
lipid peroxidation were reversed by these nutraceuti-
cals toward the control values. It can be concluded that, 
in diabetic patients, oxidative stress contributes to mem-
ory and learning deficits, suggesting that antioxidants 
including  vitamin E and melatonin are able to amelio-
rate cognitive impairments in diabetes [124].
Administration of melatonin in STZ-induced diabetic 
rats with elevated level of glial fibrillary acidic protein 
(GFAP) and S100B, as an indicator of astrogliosis, pre-
vents lipid peroxidation, GFAP and and S100B synthe-
sis and the loss of neural cell adhesion molecule, with 
these effects being associated with the improvement of 
cognitive ability [125, 126]. Melatonin may show these 
effects through its antioxidant activity contributing to 
the increased level of brain antioxidant, decreased brain 
NOSs activities and plasma cytokines levels, and inhibi-
tion of astrocytes apoptosis playing an important role in 
the CNS homeostasis [104, 127, 128]. Inhibition of oxida-
tive stress-induced activation of Poly(ADP-ribose) poly-
merase (PARP) cascade is another mechanism by which 
melatonin can improve high glucose-induced changes 
in neurotransmitter (glutamate and gamma-Aminobu-
tyric acid (GABA)) levels and neurobehavioral param-
eters in diabetic rats with neuropathy; over-activation of 
PARP in response to ROS-induced DNA damage initi-
ates an energy-consuming cycle leading to the depletion 
of intracellular  NAD+ and ATP culminating into energy 
failure and cell death [129, 130]. A 2-week combination 
treatment with nicotinamide (300, 1000 mg/kg/day) and 
melatonin (3, 10 mg/kg/day), or their application as sin-
gle therapeutic agents ameliorated the neurobehavioral 
parameters, and GABA and glutamate levels. In general, 
they showed that concurrent suppression of oxidative 
stress-PARP overactivation pathway can be valuable in 
the therapy of DM-related CNS disorders [130].
Depression DM patients are approximately three times 
more probable to develop depression [131, 132]. Even 
pregnant females with gestational diabetes have greater 
incidence of pregnancy-related depression [133, 134]. 
Similar to other complications, hyperglycemia is corre-
lated with depression [135], and glycemic therapy reduces 
depression risk even postpartum depression [136, 137]. 
Antioxidant defense breakdown may occur in chronic 
depression, due to a promoted ROS production and an 
attenuated antioxidant system activity [138].
Regarding antioxidant properties of melatonin, Ergenc 
and co-workers examined melatonin  effects  on  S100B, 
AGE  receptor (AGER), and AGE levels, oxidative 
stress, and anxiety and depressive  like-behaviors in 
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streptozotocin-mediated diabetic rats. They showed that, 
in addition to the amelioration of anxiety and depres-
sive like-behaviors,  melatonin reversed  DM-mediated 
reduction of S100B and GSH, and enhancement of AGE 
and MDA levels, indicating anxiolytic and antidepres-
sant potentials in diabetic rats via normalizing oxidative 
stress, S100B, and AGE/AGER in the hippocampus and 
prefrontal cortex [69].
Furthermore, Rebai et  al. also elucidated that mela-
tonin  and  fluoxetine decreased anxiety and depression 
signs, and Hemoglobin A1C (HbA1c) levels in diabetic 
rats. Melatonin  and  fluoxetine diminished thiobarbitu-
ric acid reactive substances in both cortices. The activity 
of CAT was restored by melatonin and fluoxetine, while 
only melatonin ameliorated GPx and glutathione S-trans-
ferases (GST) activity in the prefrontal cortex. Moreover, 
melatonin restored GPx activity in the hippocampus, 
while fluoxetine had no impact. Overall, they illustrated 
that antioxidants and antidepressants can counter oxida-
tive disorders and mood related to DM [139]. Altogether, 
melatonin is a promising therapeutic agent for the treat-
ment of CNS-related complications of DM and further 
studies are needed to be carried out to prove its efficacy 
and find possible actions mechanisms as well. Table  3 
summarizes investigations evaluating the effect of mela-
tonin on CNS-related complications of diabetes.
Therapeutic potentials of melatonin for diabetic 
neuropathy
Neuropathy is a common complication of diabetes mel-
litus which approximately affects life quality of 50% of 
diabetic patients [140]. Oxidative stress and inflamma-
tion induced by hyperglycemia plays an important role 
in the pathogenesis of diabetic neuropathy [141]. The 
high incidence of diabetic neuropathy is due to the high 
oxygen requirement of the brain, high content of polyun-
saturated fatty acids (PUFAs) and inefficient antioxidant 
capacity of the brain tissue, which results in the increased 
vulnerability of brain to diabetes-induced oxidative stress 
[128]. Prolonged hyperglycaemia promotes hippocam-
pal and cortical neuron apoptosis in diabetic patients 
leading to the moderate impairments in cognitive func-
tion and neurodegenerative diseases such as Alzheimer’s 
disease [142]. Diabetes mellitus also damages somatic or 
Table 3 Studies of melatonin effects on CNS‑related complications of diabetes





In vivo dose (animal) In vitro concentration 
(cell type)
10 mg/kg/day (male Wistar 
rats)
– Intraperitoneal 2 weeks Total antioxidant status, 
GSH, GPx, lipid peroxi-
dation, IL-1β and IL-4 
Antioxidant effects [128]
10 mg/kg/day (male Wistar 
rats)






10 mg/kg/day (Male Wistar 
rats)




10 mg/kg/day (male Wistar 
rats)





ity in the cerebel-




1 mg/kg/day (Male albino 
rattus norvegicus rats)





10 mg/kg/day (male Wistar 
rats)
– Intraperitoneal 2 weeks NOS Anti-apoptotic effects
Antioxidant effects
[104]
3, 10 mg/kg/day (male 
Sprague–Dawley rats)








10 mg/kg/day (male Wistar 
rats)
– Intraperitoneal 4 weeks S100B and GSH, and 






10 mg/kg/day (male Wistar 
rats)




signs, and HbA1c 
levels
[139]
Page 10 of 20Pourhanifeh et al. Diabetol Metab Syndr           (2020) 12:30 
autonomic nerves causing neuropathic pain, which con-
tributes to the disruption of patients’ daily functions and 
reduction of life quality [143]. Due to the role of oxidative 
stress in the induction of diabetic neuropathy, adminis-
tration of antioxidants such as melatonin may be a thera-
peutic approach to prevention of diabetic neuropathy 
(Fig. 1c).
Melatonin secretory patterns is disturbed in dia-
betic patients with autonomic neuropathy indicating a 
complex interaction between melatonin dynamics and 
autonomous neuropathy [144, 145]. Administration of 
melatonin has been reported to prevent hyperglycemia-
induced neurotic damage and occurrence of diabetic 
neuropathy characterized by increasing motor nerve 
conduction velocity (MNCV) and sciatic nerve diameter 
as well as reduction of thermal hyperalgesia [146, 147]. 
The antihyperalgesic effect of melatonin is suggested to 
be mediated by the inhibition of l-arginine–NO path-
way and induction of opioidergic system [148]. Further-
more, the analgesic properties of melatonin have been 
reported to results from it activity on  melatonin  MT2 
receptor through modulation of brainstem descending 
antinociceptive pathways [149, 150]. In dorsal root gan-
glia neurons of mice, the analgesic effects of  melatonin 
cause from MT2-dependent and independent pathways. 
The MT2-dependent pathway mediates by the activation 
of RAR-related orphan receptor alpha (RORα) leading to 
the inhibition of MAPK1 and subsequent calcium sign-
aling pathways; this effect results in the c-fos, calcitonin 
gene-related peptide (CGRP), and neuro-inflammatory 
cytokines such as tumor necrosis factor (TNF)-α and 
IL-1β. The MT2-independent pathway mediates by inhi-
bition of the expression of nitric oxide synthase 1 (NOS1) 
[151].
As mentioned previously, high glucose induces oxida-
tive stress and increases  Ca2+ ion entry playing impor-
tant roles in the pathogenesis of diabetic neuropathy 
[152]. Treatment with melatonin improves hippocampal 
injury and peripheral neuropathic pain in STZ-induced 
diabetic rats; these protective activities of melatonin are 
characterized by the improvement in the spatial naviga-
tion memory and results from electrophysiological stud-
ies including tibial motor nerve conduction and cortical 
tibial nerve somatosensory evoked potentials [153–155]. 
Melatonin inhibits oxidative stress-induced  Ca2+  mobi-
lization through transient receptor potential (TRP) mel-
astatin 2 (TRPM2) and TRP vanilloid type 1 (TRPV1) 
channels resulting in the prevention of mitochondrial 
depolarization, intracellular ROS production and apop-
tosis in neurons [153]. Histopathological, immunohisto-
chemical and ultrastructural studies also have confirmed 
the neuroprotective effect of  melatonin  in STZ-induced 
diabetic rats with peripheral and central neuropathy. In 
the sciatic nerves, melatonin has been reported to reduce 
vacuolization of the myelin sheath, axon–myelin separa-
tion and the number of degenerated fibers. In cerebral 
cortices, melatonin-treated diabetic rats showed the 
reduction in the neurodegenerative and necrotic changes; 
spongiosis and reactive astrogliosis were absent and scat-
tered pyknotic neurons with perineural vacuolations and 
swollen neurons with karolysis were remarkably reduced 
in animals with cerebral diabetic neuropathy [156, 157].
The modulatory effect of melatonin on inflammatory 
and autophagy pathways is considered as an impor-
tant mechanism against diabetic neuropathy. Melatonin 
elevates the expression of nuclear factor erythroid 2‐
related factor 2 (Nrf2) resulting in the up-regulation 
of the expression of  phase II antioxidant/detoxifying 
enzymes such as heme oxygenase-1  (HO-1) decreas-
ing oxidative stress and activation of nuclear factor-κB 
(NF‐κB) cascade [158].The expression of PINK1 and 
microtubule-associated proteins 1A/1B light chain 3 B 
(LC-3 B), mitophagy markers, increased in neuronal cells 
following treatment with melatonin. Since silencing of 
PINK1 expression impairs melatonin-mediated reduc-
tion of mitochondrial ROS production and apoptotic 
marker activation, it is suggested that melatonin pre-
vents neuronal cell apoptosis under high glucose condi-
tions through stimulating PINK1 expression; this effect 
of melatonin has been demonstrated to be MT2 receptor 
dependent [159].
Erectile dysfunction is an intractable health problem 
impressing more than half of male diabetic patients. 
Evaluation of the effect of melatonin on erectile dysfunc-
tion in diabetic rats revealed that melatonin treatment 
improves the erectile function through ameliorating neu-
ropathy in dorsal penile nerve and major pelvic ganglion. 
This effect of melatonin is accompanied by alleviation of 
fibrosis through reduction of collagen deposition, oxida-
tive stress, and p38 MAPK signaling pathway in penis 
[160]. Retina neuronal cell apoptosis is one of the main 
pathological symptoms of diabetic retinal neuropathy, 
which induces by the high glucose-induced excessive 
production of ROS resulting in the structure and func-
tion damages of mitochondria triggering the release of 
apoptosis-inducing factors and subsequent activation of 
neuronal apoptosis process [161]. Table  4 summarizes 
in vivo and in vitro studies evaluating the effect of mela-
tonin on diabetic neuropathy.
Melatonin is an appropriate agent for the treatment 
of diabetic nephropathy
Diabetic nephropathy, as one of the main microvascular 
complications of both type 1 and type 2 diabetes mel-
litus, is the most frequent cause of end-stage renal dis-
eases. Diabetic nephropathy is characterized by nephron 
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enlargement, glomerular hyperfiltration as well as the 
hypertrophy of mesangial cells, which eventually devel-
ops into glomerulosclerosis [162]. Several mechanisms 
have been proposed for diabetic nephropathy pro-
gression and development, including lipid disorders, 
oxidative stress, pro-fibrotic and fibrotic cytokines gener-
ation (such as fibronectin (FN)-1, plasminogen activator 
inhibitor (PAI)-1, and connective tissue growth factor 
(CTGF) [163–166].
As mentioned above, ROS have a key role in diabetic 
complications [167]. In hyperglycemia state, the persis-
tent oxidative stress contributes to damage to the nuclear 
DNA and the mitochondrial genetic material [168].
Table 4 Studies of melatonin effects on diabetic neuropathy
Type of study Route 
of administration
Treatment duration Target Effect(s) Refs.
In vivo dose (animal) In vitro 
concentration (cell 
type)
50 mg/kg/day (male 
Wistar rats)









10 mg/kg/day (male 
Sprague–Dawley 
rats)






10 mg/kg/day (male 
Wistar albino rats)




10 mg/kg/day (male 
Wistar albino rats)
– Intraperitoneal 6 weeks – Increased MNCV 





– Intraperitoneal 1 week – Decreased thermal 
hyperalgesia
[147]
10 mg/kg/day (male 
Sprague–Dawley 
rats)






3, 10 mg/kg/day 
(male Sprague–
Dawley rats)
– Oral 2 weeks (seventh and 
eighth week after 
diabetes induction)






3, 10 mg/kg/day 
(male Sprague–
Dawley rats)
– Oral 2 weeks MDA
NAD+, ATP, PARP
Improved functional 




10 mg/kg/day (female 
Wistar albino rats)









10 mg/kg/day (male 
Wistar rats)







10 mg/kg/day (male 
albino rats)
– Intraperitoneal 6 weeks Myelin sheaths, nerve 
fibers and endoneu-







Mild local axon 
separation from 
myelin sheaths was 
detected
[157]
– 1 μmol/L (SK‐N‐MC, 
SH‐SY5Y)
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Hyperglycemia leads to apoptosis in different types of 
cells in diabetic nephropathy, such as the proximal tubule 
epithelial cells [169]. It has been previously explained that 
the apoptosis occurs through activating numerous intra-
cellular signaling pathway [170]. Now, it is acknowledged 
that hyperglycemia mediates apoptosis and promotes the 
gradual loss of kidney function in diabetic nephropathy 
[171].
Structural melatonin’s features, such as electron-
richness, hydrophilicity, and lipophilicity yield potential 
impacts of this agent in terms of antioxidant capacity and 
insulin secretion impact by the MT1 receptor [172]. Mel-
atonin elevates numerous antioxidant enzymes, such as 
SOD, peroxidase, GSH and lipid peroxidase [29]. Mela-
tonin easily crosses cell membranes and leads to protec-
tion against free radical-induced damage to biomolecules 
[173].
Diabetic kidney is more sensitive to  ischemia/reper-
fusion  (I/R) injury correlated with enhanced oxidative 
stress. In a 4-week in vivo study, Shi et al. evaluated the 
therapeutic effects of melatonin on renal I/R of dia-
betic rats. Animals were treated with or without  mela-
tonin, and renal I/R injury was induced by clamping right 
and left renal pedicles for 30  min followed by  reperfu-
sion  for 48 h. Diabetic rats treated with melatonin were 
protected against renal injury, in aspects of oxidative 
stress and cell apoptosis in kidney [174].
In accordance with the findings of Parving et al. [175], 
Motawi and colleagues indicating that the combination 
of melatonin with Losartan Potassium considerably ame-
liorates the urine creatinine and serum uric acid levels as 
well as kidney injury molecule (KIM-1) level, as glomeru-
lar damage index [176]. In addition, these agents decrease 
diabetes mellitus effects on the level of oxidative stress 
biomarkers, where melatonin and LSP combination sig-
nificantly ameliorate the levels of GSH, SOD, MDA, and 
NO in rats with diabetic nephropathy [176]. Aberrant 
angiogenesis has a pathological role in diabetic nephrop-
athy; however, endothelial-to-mesenchymal transition 
of glomerular endothelial cells results in enhanced per-
meability, leading to proteinuria [177, 178]. Melatonin 
inhibits endothelial-to-mesenchymal transition (EMT) 
in glomerular endothelial cells exposed to transforming 
growth factor-β2 (TGF-β2) and in the glomeruli of dia-
betic rats; this effect is mediated by the up-regulation 
of miR-497 expression leading to inhibited RhoA/Rho 
kinase (ROCK) activity [179].
Rashed and his colleagues have shown that incuba-
tion of mesenchymal stem cells with melatonin before 
administration resulted in the improvement of autophagy 
pathway, elevation of SOD1 level and further decline 
in TGF-β level in the kidney tissue of diabetic rats 
compared to those treated with mesenchymal stem cells 
alone [180].
Onk et  al. [173] found enhanced IL-33 levels in the 
kidney tissue following contrast-induced nephropathy 
(CIN) in diabetic rats; administration of melatonin in 
these animals considerably attenuated kidney tissue con-
centrations of inflammatory cytokines, oxidative stress 
biomarkers, and IL-33, indicating potential roles of mela-
tonin in the treatment of diabetic nephropathy. Mela-
tonin also reduced serum creatinine in rats with diabetic 
nephropathy.
In an in vitro study, Ji et al. evaluated protective roles 
of melatonin against angiotensin II–mediated diabetic 
nephropathy. They revealed that melatonin  markedly 
enhanced the proliferative rate of cells and decreased 
angiotensin II-mediated apoptosis, as shown by declined 
concentrations of apoptotic proteins expression, such as 
Bax and caspase-3. Also, the recovery of mitochondrial 
function and reduced oxidative stress were implicated in 
the protective effect of melatonin. Additionally, the inhi-
bition of Janus kinase (JAK)-signal transducer and acti-
vator of transcription (STAT) pathway demonstrated that 
cytokine-induced inflammation is also targeted by mela-
tonin [181].
Gumustekin et  al. assessed the efficacy of melatonin 
in the treatment of rats with diabetic nephropathy. After 
14 weeks of diabetes induction, 10 mg/kg melatonin was 
given to diabetic rats for 5  days. Melatonin could not 
improve hemorheological abnormalities, such as erythro-
cyte deformability and aggregation, but ameliorated renal 
injuries by suppressing apoptosis process [182].
It is obvious that melatonin affects various signaling 
pathways resulting in the reduction of diabetes-induced 
renal damages (Fig. 1d); however, further studies should 
be performed to find the exact mechanism of action of 
melatonin for diabetic nephropathy. Notably, it seems 
that melatonin deserves to be used in the human trials 
as a complementary treatment to assess its effectiveness 
in the treatment of patients with diabetic nephropathy. 
Herein, Table 5 summarizes in vivo and in vitro studies 
on the effect of melatonin on diabetic nephropathy.
Melatonin and diabetic wound healing
Diabetic wounds are leading cause of diabetes-associated 
amputations, resulting in poor quality of patients’ life and 
high medical cost [183]. It is characterized by impaired or 
diminished production of growth factor, granulation tis-
sue quantity, epidermal barrier function, collagen accu-
mulation, macrophage function, and angiogenic response 
[184, 185]. Disruption in healing process may result from 
ischemic conditions caused by intrinsic factors such 
as signaling abnormalities, neuropathy, and vascular 
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problems as well as extrinsic factors including trauma 
and wound infection [186, 187]. Denervation with sen-
sory abnormalities of the nerves further exacerbates the 
slowed microcirculation [188].
Melatonin, which is also produced in the skin [189], 
accelerates wound healing in full-thickness incisional 
wounds [190]. Ji e al. carried out an investigation to eval-
uate melatonin potential in improving diabetic wound 
healing and the possible mechanism. Treatment of mice 
bone marrow-derived endothelial progenitor cells (EPCs) 
with melatonin inhibits advanced AGE-mediated cellu-
lar dysfunction and apoptosis. Melatonin is reported to 
Table 5 The application of melatonin for the treatment of diabetic nephropathy
ND not defined





In vivo dose (animal) In vitro concentration 
(cell type)
50 mg/L (male 
Sprague–Dawley rats)
50 μM (human renal 
GEnCs)




of GEnCs through modulating 
miR-497/ROCK signaling
[179]
– 5 μM (mesenchymal 
stem cells)
– 24 h Beclin-1 MSCs therapy considerably ame-
liorated the renal functions. 
Its impact was intensified by 
melatonin pre-incubation.
[180]
200 µg/kg (male ZDF 
rats)
– Intraperitoneal 8 weeks HSP70, Caspase3, TGF-
β, KIM-1
Melatonin revealed potential 
effects on protecting rats from 
deleterious action of diabetic 
nephropathy followed by its 
combination with rowatinex.
[197]
– 0/1, 1 mM (mouse 
podocytes)
– 48 and 72 h Bax/Bcl–2, Jak/STAT Melatonin showed anti-apop-
totic effects in AngII-induced 
podocyte injury
[181]
200 µg/kg/day (male 
Wistar strain albino 
rats)
– Oral 60 days HSP70
Caspase3, TGF-β KIM-1
The combination of melatonin 
and Losartan Potassium 
exerted the most potent 
effects on treating the deleteri-
ous action of diabetes on rat 
kidney
[176]
20 mg/kg/day (male 
Sprague–Dawley rats)
– Intraperitoneal 7 days MPX, IL-33
IL-1β
IL-6
Suppression of IL-33 with 
melatonin yields therapeutic 
potentials in diabetic kidney 
disease with contrast-induced 
nephropathy
[173]
10 mg/kg (male 
Sprague–Dawley rats)
– Intraperitoneal 4 weeks SIRT1/Nrf2/HO-1 
signaling
Antioxidants effects [174]
20 mg/L (male Wistar 
strain albino rats)
– Drinking water 4 weeks NADPH oxidase (NOX) Melatonin showed antioxidant 
and nephroprotective effects
[198]
10 mg/kg/day (male 
db/db mice)
– Intraperitoneal 30 days SOD, CAT, MDA Antioxidant effects [199]
– 25 μM (kidney cells of 
db/db mice)




10 mg/kg/day (male 
Wistar rats)
– Intraperitoneal 5 days Blood glucose, HbA1c Antioxidant effects
Anti-apoptotic effects
[182]
0.02% of drinking water 
(male Sprague–Daw-
ley rats)
– Drinking water 4 weeks TGF-β1, FN Potential effects on early 
changes in diabetic kidney
[201]
200 μg/kg/day (male 
Sprague–Dawley rats)
– Intraperitoneal 15 days SOD, CAT, GST, NO Antioxidants effects [202]
10 mg/kg/day (male 
Sprague–Dawley rats)
– Intraperitoneal 8 weeks xanthine oxidase (XO)
MDA, GSH-Px, SOD
Antioxidants effects [203]
200 μg/kg/day (male 
Wistar strain albino 
rats)
– Intraperitoneal 4 weeks IGF-1, anti-laminin β1 Antioxidants effects [204]
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enhance autophagy flux characterized by the elevation of 
LC3 level, and reduction of p62 accumulation. Moreo-
ver, AMPK/mTOR signaling pathway is implicated in 
stimulating autophagy via melatonin. In a diabetic wound 
healing model, melatonin improved disrupted wound 
healing. Therefore, melatonin is suggested to improve 
disrupted wound healing through inhibiting apoptotic 
events by stimulation of autophagy pathway [191].
Melatonin also promotes umbilical cord blood (UCB)-
mesenchymal  stem  cells (MSCs) motility through 
enhancing cytoskeletal reorganization which this effect 
is mediated by  melatonin MT2 receptor triggering Gq 
protein alpha (Gαq)-dependent protein kinase  (PK)Cζ 
phosphorylation regulating Focal adhesion kinase (FAK)/
paxillin-mediated cell division cycle 42 (Cdc42)/actin-
related proteins (Arp2/3) activation [192].
In keratinocytes, melatonin reduces high glucose-
induced the release of inflammatory cytokines, such 
as interleukin (IL)-1β, IL-6, IL-8 and tumor necrosis 
factor-α associated with the reduction of ROS forma-
tion and the elevation of SOD activity. In diabetic wound, 
melatonin causes essential events in the healing process 
including suppression of apoptosis, promotion of migra-
tion and proliferation, reduction of oxidative stress, and 
suppression of inflammatory process in keratinocytes 
[193]. Hence, melatonin is suggested to be useful in dia-
betic foot ulcer through regulating keratinocyte activity. 
Table  6 summarizes investigations have evaluated the 
effect of melatonin on diabetic wound.
Melatonin application for diabetic patients in clinical 
practice
Raygan et  al. carried out a randomized, double-blind 
clinical trial on diabetic patients with coronary heart 
disease. Sixty patients were divided into two groups to 
receive either placebo or 10 mg melatonin for 12 weeks. 
Melatonin had appropriate impacts on glycemic control, 
HDL-cholesterol, serum levels of high-sensitivity C-reac-
tive protein (hs-CRP), blood pressure, plasma MDA, NO, 
and GSH as well as mental health parameters [194].
Kadhim et  al. performed a clinical trial on patients 
with type 2 diabetes who were poorly controlled with 
metformin. Forty-six patients with type 2 diabetes were 
divided into three groups and were treated for 90  days 
with daily oral administration of melatonin (10 mg), zinc 
acetate (50 mg), or both supplements in addition to the 
routine used metformin or placebo. Daily intake of zinc 
and melatonin  reduced the level of microalbuminu-
ria  and ameliorated the lipid profile. In conclusion, the 
addition of these supplements to metformin ameliorated 
the tissue responses to this oral hypoglycemic agent [67].
Another investigation was conducted to assess thera-
peutic efficacy of melatonin and zinc in glycemic con-
trol of type 2 diabetic patients poorly controlled with 
metformin. The supplements were administered at the 
same doses in 90 days. They revealed that the combina-
tion of zinc acetate and melatonin, when utilizes alone or 
in combination with metformin, ameliorates fasting and 
post-prandial glucose levels in diabetic subjects [195]. 
Table 6 Investigations on melatonin and diabetic wound healing
Type of study Route 
of administration
Treatment duration Targets Effect(s) Refs.
In vivo dose (animal) In vitro 
concentration (cell 
type)
1.2 mg/kg (male 
Sprague–Dawley 
rats)





the quality of 
wound healing and 
scar formation
[190]
– 10, 20, 50, 100, and 
200 μM (endothelial 
progenitor cells 
(EPCs))




dysfunction of EPCs 






Umbilical cord blood 
(UCB)‐MSCs
24 h FAK/paxillin, Cdc42/
Arp2/3, PKC, Gαq 
and




mouse skin wound 
sites
[192]
– 1 mM keratinocytes 24 h TNF-α, IL-1β, IL-6, IL-8, 
ROS, SOD, MDA






Page 15 of 20Pourhanifeh et al. Diabetol Metab Syndr           (2020) 12:30  
Regarding what discussed melatonin supplementations 
could be used for diabetic complications in human stud-
ies. To prove the effectiveness and safety of melatonin 
as a complementary treatment for diabetic patients, it is 
important to design large clinical trials.
Conclusions
Due to the rapid increase of the global DM prevalence, 
exploring efficient therapies for diabetic complications 
is an important issue. Routine treatments for DM are 
generally based on metabolic control, and existing drugs 
cannot totally control the development of complica-
tions. Researches have recently indicated the capabil-
ity of melatonin to modulate various signaling pathways 
and demonstrated its therapeutic and preventive effects 
in several diseases, such as DM. Preclinical and clinical 
studies have shown different mechanisms of action of 
melatonin including reduction of glucose production, 
and improvement of pro-inflammatory pathways as well 
as oxidative stress state in DM patients. Previously, it 
has been revealed that melatonin treatment ameliorates 
DM through regulating the lipid and glucose metabo-
lism, reducing the insulin resistance and increasing the 
sensitivity to insulin in experimental models of DM. It 
will be crucial to perform human clinical trials utiliz-
ing combinations of melatonin with current therapeutic 
agents for treatment and prevention of cardiomyopathy, 
neuropathy, retinopathy, nephropathy, and other diabetic 
complications.
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